preloader

INSULIN 186(E)

(Published in Part II, Section 3, Sub-section (ii) of

the Gazette of India, Extraordinary, dated the 29th January, 2008)

National Pharmaceutical Pricing Authority

Ministry of Chemicals and Fertilizers

Government of India

ORDER

New Delhi, the 29th January, 2008

S.O. 186 (E) – In exercise of the powers, conferred by sub-paragraphs (1)/(2)/(4) of paragraph 8 of the Drugs (Prices Control) Order, 1995, read with No. S.O. 637 (E) dated the 4th September, 1997 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority hereby fixes/revises the prices as specified in column (5) of the table hereto annexed as the retail price/revised retail price, exclusive of excise duty, sales taxes/VAT and local taxes, if any, and in column (6) equivalent MRP inclusive of excise duty, education cess, Sales Tax/VAT in relation to each of the formulations specified in the corresponding entry in column (2) of the said Table with the pack size specified in the corresponding entries in column (3) thereof; manufactured / imported by M/s. Eli Lilly and Company (India) Pvt. Ltd.

TABLE

 

SI. No. Name of the formulation Pack Size Existing Retail Price (Rs.) Retail Price without Excise Duty Sales Tax /VAT and Local Tax, if any (Rs.) Equivalent MRP* (inclusive of all taxes) (Rs.)
(1) (2) (3) (4) (5) (6)
“1
Monocomponent Insulin

Humalog 100 IU / ml
Insulin Lispro
Qty. 8870 Cartridges B.no. A 415359

3 ml

Cartridge

398.01 397.74 412.92
2 Monocomponent Insulin

Humalog 100 IU / ml
Insulin Lispro
Qty. 8975 Cartridges B.no. A 401269

3 ml

Cartridge

398.01 397.38 413.27
3 Monocomponent Insulin

Humalog Mix 25 100 IU / ML
25% Insulin Lispro and 75% Insulin Lispro
Protamin suspension, r-DNA origin
Qty. 50000 Cartridges B.no. A 403605

3 ml

Cartridge

398.49 397.38 413.27
4 Monocomponent Insulin

Humalog Mix 50 100 IU / ML
50% Insulin Lispro and 50% Insulin Lispro
Protamin suspension, r-DNA origin
Qty 5250 Cartridges B.no. A 416511

3 ml

Cartridge

398.01 397.38 413.27
5 Monocomponent Insulin

Humalog Pen  100 IU / ML
(Insulin Lispro)
Qty 9700 Disposable pen  B.no. A 405728

3 ml disposable

Pen

588.75

523.23

.

544.15
6 Monocomponent Insulin

Humalog Mix 25 Pen 100 IU / ML
25% Insulin Lispro and 75% Insulin Lispro
Protamin suspension, r-DNA origin
Qty 8655 Disposable pen B.no. A 403587

3 ml disposable

Pen

588.75 523.23 544.15
7 Monocomponent Insulin

Humalog Mix 50 Pen 100 IU / ML
50% Insulin Lispro and 50% Insulin Lispro
Protamin suspension, r-DNA origin
Qty 8900  Disposable pen B.no. A 402237

3 ml disposable

Pen

588.75 523.23 544.15
8 Monocomponent Insulin

Hum insulin regular 100 IU / ml
Insulin human Injection
Qty 14800 Cartridges B. A 408485

3 ml

Cartridge

231.87 203.32 211.45
9 Monocomponent Insulin

Humalog Mix 25 100 IU / ml
25% Insulin Lispro and 75% Insulin Lispro
Protamin suspension, r-DNA origin
Qty 20000 Cartridges B.no. A 420366

3 ml

Cartridge

398.01 397.81 413.72
10 Monocomponent Insulin

Humininsullin 30/70 100 IU / ml
30% Neutral Insulin solution &70%
Isophane suspension Human
Qty 20500  Cartridges B.no. A 380178

3 ml

Cartridge

199.84 203.66 211.80
11 Monocomponent Insulin

Humalog Mix 50- 100 IU / ML
50%  Insulin lispro & 50% Insulin lispro
Protamin suspension, r-DNA origin
Qty 66150 Cartridges B.no. A 427418

3 ml

Cartridge

398.01 397.21 413.09
12 Monocomponent Insulin

Humalog 100 IU / ML
(Insulin Lispro)
Qty 60000 Cartridges B.no. A 427433

3 ml

Cartridge

398.01 397.26 413.15
13 Monocomponent Insulin

Humalog Pen 100 IU / ML
(Insulin Lispro)
Qty 9550  Disposable pen B.no. A 396989

3 ml disposable

Pen

588.75 525.00 546.00
14 Monocomponent Insulin

Huminsulin Regular (100 IU / ML)
Insulin Human Injection
Qty 11925 Vial B.no. HIR 067C

10ML

Vial

333.68 369.87 384.66
15 Monocomponent Insulin

Huminsulin 30/70 – 100 IU / ML
(30% Neutral Insulin Solution & 70% Isophane Suspension Human)
Qty 22461 Vial B.no. HIM 331

10ML

Vial

333.68 369.87 384.66
16 Monocomponent Insulin

Huminsulin 30/70 – 100 IU / ML
(30% Neutral Insulin Solution & 70% Isophane Suspension Human)
Qty 22458 vials  B.no. HIM 304

10ML

Vial

366.90 369.12 383.88
17 Monocomponent Insulin

Huminsulin Regular (100 IU / ML)
Insulin Human Injection
Qty 3332 Vial B.no. HIR 068A

10ML

Vial

333.68 369.12 383.88
18 Monocomponent Insulin

Huminsulin NPH (100 IU / ML)
(Isophane Insulin Human Suspension)
Qty 5777 Vial B.no. HIN 070

10ML

Vial

333.68 369.12 383.88
19 Monocomponent Insulin

Huminsulin 30/70 – 100 IU / ML

(30% Neutral Insulin Solution

& 70% Isophane Suspension Human)

Qty 22469 vials  B.no. HIM 306

10ML

Vial

333.68 369.12 383.88”

*Subject to actual payment of Government levies/taxes, as applicable.

Note :

(a)           The prices fixed are the maximum retail prices in column no. (6) (inclusive of excise duty, Sales Tax/VAT and local taxes if any) for the specified pack and packs of similar strength, and companies cannot claim exemption on any ground therefrom, unless specifically permitted by the Government/NPPA through an order.

(b)           The companies/manufacturers may Add taxes only if they have paid actually to the Government on the price mentioned in the column (5).  If there is any variation in the MRP (inclusive of the taxes), the same may be intimated to the NPPA in the Form-V of DPCO, 1995.

(c)           For different packing material used or any special feature claimed, companies are required to approach NPPA for approval/fixation of specific prices.

(d)           The prices fixed/notified hereinabove under the provisions of DPCO, 1995 have to be mandatorily implemented by the manufacturing/marketing company notwithstanding its status of compliance of conditions for such formulation pack under the Drugs and Cosmetics Act, 1940.

(e)           These prices/revised prices shall be made effective within 15 days of receipt of this order as required under sub para 14(1) of DPCO, 1995.  The necessary price-list should also be issued as required under sub-paragraph (3) of paragraph 14 of the Drugs (Prices Control) Order, 1995.

(f)            The manufacturer and marketing company for the above said formulation shall be required to take the requisite prior approval from the Competent Authority for any change in the composition of the above said formulation with written prior intimation to the National Pharmaceutical Pricing Authority.

[PN/98/2008/F./F. No. 8(8)/2007/D.P./NPPA-Div.-II]

                RAJIV WADHAWAN, Deputy Director

Last Page Updated: 03-06-2019